US3995041A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Derivatives of 2-substituted-hydroxyanilino-hexahydro-2H-benzo[α]quinolizines
Assignee: Bayer Corp
•
Filing: 1975-10-30
•
Granted: 1976-11-30
•
Expires: 1995-10-30
Abstract
Abstract 2-Substituted-hydroxyanilino-hexahydro-2H-benzo[ alpha ]quinolizines of the structural formula, IN WHICH R1 is a hydrogen atom or an alkanoyl group of 2 to 4 carbon atoms and each of substituents R2, R3, R4, R5, and R6 is a hydrogen atom, a hydroxyl, or a methyl group, such that at least one of the latter substituents is a hydroxyl group, exhibit coronary vasodilating activity.
Inventors
- 👤 Herbert John Havera
- 👤 Richard Don Johnson
- 👤 Horacio Vidrio
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 05:03
CPC Classifications
C; C07; C07D; C07D455/00; C07D455/03; C07D455/04; C07D455/06; A; A61; A61P; A61P9/00; A61P9/08; A61P9/10
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
75 words
A compound having the formula ##SPC6## or a non-toxic pharmacologically acceptable salt thereof wherein: R 1 is selected from the group consisting of hydrogen or an alkanoyl group having from 2 to 4 carbon atoms; and each of substituents R 2 , R 3 , R 4 , R 5 , and R 6 is selected from the group consisting of hydrogen, methyl, or hydroxyl provided that at least one of said substituents is hydroxyl.
Claim 2
Dependent Claim
75 words
A compound having the formula ##SPC6## or a non-toxic pharmacologically acceptable salt thereof wherein: R 1 is selected from the group consisting of hydrogen or an alkanoyl group having from 2 to 4 carbon atoms; and each of substituents R 2 , R 3 , R 4 , R 5 , and R 6 is selected from the group consisting of hydrogen, methyl, or hydroxyl provided that at least one of said substituents is hydroxyl.
Claim 3
Dependent Claim
7 words
The compound of claim 1, 2-(2-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine dihydrochloride.
Claim 4
Dependent Claim
7 words
The compound of claim 1, 2-(3-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine dihydrochloride.
Claim 5
Dependent Claim
8 words
The compound of claim 1, 2-(4-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine monoxalate monohydrate.
Claim 6
Dependent Claim
7 words
The compound of claim 1, 2-(4-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine dihydrochloride.
Claim 7
Dependent Claim
8 words
The compound of claim 1, 2-(2,4-dihydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine dihydrobromide hydrate.
Claim 8
Dependent Claim
7 words
The compound of claim 1, 2-(2,6-dihydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine hydrochloride.
Claim 9
Dependent Claim
7 words
The compound of claim 1, 2-(3,4-dihydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine monooxalate.
Claim 10
Dependent Claim
8 words
The compound of claim 1, 2-(2-methyl-4-hydroxyanilino-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine monooxalate monohydrate.
Claim 11
Dependent Claim
8 words
The compound of claim 1, 2-(2,3,5,6-tetramethyl-4-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine dihydrochloride monohydrate.
Claim 12
Dependent Claim
7 words
The compound of claim 1, N-(4-hydroxyphenyl)-N-(1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizin-2-yl)propionamide hydrochloride.
Claim 13
Dependent Claim
116 words
In a therapeutic method of producing coronary vasodilation by administration by conventional means of a coronary vasolidating agent to an individual in whom that therapy is indicated, the improvement which comprises: administering to the individual an effective coronary vasodilating amount of a compound having the formula ##SPC7## or a non-toxic pharmacologically acceptable salt of said compound wherein: R 1 is selected from the group consisting of hydrogen or alkanoyl having from 2 to 4 carbon atoms; and each of substituents R 2 , R 3 , R 4 , R 5 , and R 6 is selected from the group consisting of hydrogen, methyl, or hydroxyl such that at least one of said substituents is hydroxyl.
Claim 14
Dependent Claim
116 words
In a therapeutic method of producing coronary vasodilation by administration by conventional means of a coronary vasolidating agent to an individual in whom that therapy is indicated, the improvement which comprises: administering to the individual an effective coronary vasodilating amount of a compound having the formula ##SPC7## or a non-toxic pharmacologically acceptable salt of said compound wherein: R 1 is selected from the group consisting of hydrogen or alkanoyl having from 2 to 4 carbon atoms; and each of substituents R 2 , R 3 , R 4 , R 5 , and R 6 is selected from the group consisting of hydrogen, methyl, or hydroxyl such that at least one of said substituents is hydroxyl.
Claim 15
Dependent Claim
13 words
The method of claim 12, in which said compound is 2-(4-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]-quinolizino monoxalate monohydrate.
Claim 16
Dependent Claim
12 words
The method of claim 12, in which said compound is 2-(4-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]-quinolizine dihydrochloride.
Claim 17
Dependent Claim
14 words
The method of claim 12, in which said compound is 2-(2,4-dihydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[ α]quinolizine dihydrobromide hydrate.
Claim 18
Dependent Claim
12 words
The method of claim 12, in which said compound is 2-(2,6-dihydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine hydrochloride.
Claim 19
Dependent Claim
12 words
The method of claim 12, in which said compound is 2-(3,4-dihydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine monooxalate.
Claim 20
Dependent Claim
13 words
The method of claim 12, in which said compound is 2-(2-methyl-4-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[.alpha.]quinolizine monooxalate monohydrate.
Claim 21
Dependent Claim
13 words
The method of claim 12, in which said compound is 2-(2,3,5,6-tetramethyl-4-hydroxyanilino)-1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizine dihydrochloride monohydrate.
Claim 22
Dependent Claim
12 words
The method of claim 12, in which said compound is N-(4-hydroxyphenyl)-N-(1,3,4,6,7,11β-hexahydro-2H-benzo[α]quinolizin-2-yl)propionamide hydrochloride.
References Cited (Backward Citations)
US3634431A
Cited
US3635986A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-11-30 | 1980-05-31 | 1980-11-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-11-30 | 1984-05-31 | 1984-11-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-11-30 | 1988-05-31 | 1988-11-30 | $7700.00 | Window Closed / Lapsed |